Giuseppe Lippi/LinkedIn
Oct 10, 2025, 03:09
Giuseppe Lippi: We Show Here That Red Light Therapy Offers Promise in High-Risk Patients
Giuseppe Lippi, Dean of Medicine at the University of Verona, shared on LinkedIn:
”We show here that red light therapy offers promise in high-risk patients where conventional anticoagulation is limited by bleeding risk.
Fan BE, Pasalic L, Lippi G, Hew YY, Favaloro EJ. Red Light Therapy in Thrombosis and Hemostasis. Semin Thromb Hemost. 2025 Oct 8. doi: 10.1055/a-2717-5157. Epub ahead of print.”
Read the full article in Seminars in Thrombosis and Hemostasis.
Article: Red Light Therapy in Thrombosis and Hemostasis
Authors: Bingwen Eugene Fan , Leonardo Pasalic, Giuseppe Lippi , Yu Yue Hew, Emmanuel J. Favaloro
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Jan 12, 2026, 14:46A Behcet Disease with Aortic Thrombosis: Alexandru Stieber Shares A Peculiar Case
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies